Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix John

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The Lancet. Global Health|May 13, 2022
The future is urban: integrated planning policies can enable healthy and sustainable citiesDeepti Adlakha, Felix John
Innere Medizin (Heidelberg, Germany)|October 17, 2025
[Treatment of metastatic non-small cell lung cancer]Malte Verheyen, Lea Ruge, Felix John, et al.
Innere Medizin (Heidelberg, Germany)|February 8, 2024
[Advances in the targeted treatment of non-small cell lung cancer]Lea Ruge, Felix John, Heather Scharpenseel, et al.
Frontiers in Oncology|April 17, 2026
Global disparities in access to diagnostics and therapies for advanced non-small cell lung cancer: from discovery to delivery - a reviewLea Ruge, Malte Verheyen, Felix John, et al.
Molecular Neurobiology|March 18, 2018
Increased ROS Level in Spinal Cord of Wobbler Mice due to Nmnat2 DownregulationPascal Röderer, Lara Klatt, Felix John, et al.
Frontiers in Cellular Neuroscience|September 19, 2022
ROS scavengers decrease γH2ax spots in motor neuronal nuclei of ALS model mice <i>in vitro</i>Maya Junghans, Felix John, Hilal Cihankaya, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Evaluating docetaxel effectiveness in KRAS G12C-mutated NSCLC: insights from a Real-World cohortMatthias Scheffler, Lia Tzala, Karly Louie, et al.
JTO Clinical and Research Reports|March 12, 2026
MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET InhibitionRichard Riedel, Lea Ruge, Malte Verheyen, et al.
Lung Cancer (Amsterdam, Netherlands)|August 14, 2023
Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patientsMoritz Glaser, Anna Rasokat, Darinka Prang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responsesLea Ruge, Felix John, Malte Verheyen, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The Lancet. Global Health|May 13, 2022
The future is urban: integrated planning policies can enable healthy and sustainable citiesDeepti Adlakha, Felix John
Innere Medizin (Heidelberg, Germany)|October 17, 2025
[Treatment of metastatic non-small cell lung cancer]Malte Verheyen, Lea Ruge, Felix John, et al.
Innere Medizin (Heidelberg, Germany)|February 8, 2024
[Advances in the targeted treatment of non-small cell lung cancer]Lea Ruge, Felix John, Heather Scharpenseel, et al.
Frontiers in Oncology|April 17, 2026
Global disparities in access to diagnostics and therapies for advanced non-small cell lung cancer: from discovery to delivery - a reviewLea Ruge, Malte Verheyen, Felix John, et al.
Molecular Neurobiology|March 18, 2018
Increased ROS Level in Spinal Cord of Wobbler Mice due to Nmnat2 DownregulationPascal Röderer, Lara Klatt, Felix John, et al.
Frontiers in Cellular Neuroscience|September 19, 2022
ROS scavengers decrease γH2ax spots in motor neuronal nuclei of ALS model mice <i>in vitro</i>Maya Junghans, Felix John, Hilal Cihankaya, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Evaluating docetaxel effectiveness in KRAS G12C-mutated NSCLC: insights from a Real-World cohortMatthias Scheffler, Lia Tzala, Karly Louie, et al.
JTO Clinical and Research Reports|March 12, 2026
MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET InhibitionRichard Riedel, Lea Ruge, Malte Verheyen, et al.
Lung Cancer (Amsterdam, Netherlands)|August 14, 2023
Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patientsMoritz Glaser, Anna Rasokat, Darinka Prang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responsesLea Ruge, Felix John, Malte Verheyen, et al.
Pageof 2